Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$4.75B
sum of reported positions
Reported positions
148
Changes vs prior quarter
142
17 new · 24 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 105 measured positions in 8 quarters, the typical new or larger position finished +0.6 pts against the S&P 500 and 52% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 852K | $308M | 6.5% | |
| 579K | $287M | 6.0% | |
| 301K | $279M | 5.9% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $4.2B | $4.75B |
| Positions | 155 | 148 |
| Biggest line | — | Amgen 6% |
| 2.16M |
| $273M |
| 5.7% |
| 1.05M | $196M | 4.1% |
| 1.66M | $158M | 3.3% |
| 1.39M | $149M | 3.1% |
| 2.45M | $135M | 2.8% |
NUVALENT INC | 1.05M | $130M | 2.7% |
| 6.73M | $124M | 2.6% |
| 6.19M | $116M | 2.4% |
| 1.97M | $115M | 2.4% |
| 189K | $102M | 2.1% |
| 255K | $101M | 2.1% |
| 157K | $98.1M | 2.1% |
CRINETICS PHARMACEUTICALS IN | 2.62M | $98M | 2.1% |
| 1.19M | $88.6M | 1.9% |
| 2.79M | $88.5M | 1.9% |
| 947K | $85.9M | 1.8% |
| 268K | $84.5M | 1.8% |
| 994K | $77.8M | 1.6% |
| 972K | $77.1M | 1.6% |
| 1.49M | $75.6M | 1.6% |
| 1.71M | $73.4M | 1.5% |
| 3.06M | $67.9M | 1.4% |
Avalyn Pharma (AVLN)
1.35M shares
Cg Oncology (CGON)
494K shares
Seaport Therapeutics (SPTX)
1.1M shares
Palvella Therapeutics (PVLA)
155K shares
Spyre Therapeutics (SYRE)
230K shares
Hemab Therapeutics Holdings (COAG)
550K shares
Parabilis Medicines (PBLS)
500K shares
Aura Biosciences (AURA)
1.17M shares
Molina Healthcare (MOH)
28K shares
Gmr Solutions (GMRS)
333K shares
Alamar Biosciences (ALMR)
56K shares
Mobia Medical (MOBI)
100K shares
Veradermics (MANE)
3,468 shares
Definium Therapeutics (DFTX)
8,391 shares
Viatris (VTRS)
16K shares
Cogent Biosciences (COGT)
4,870 shares
Waters Corporation (WAT)
179 shares
